The Pharmaceutical Pricing and Bidding and Procurement Guidance Center of the National Medical Insurance Administration released on the 27th the status of 26 pharmaceutical companies in each province that were rated as "especially serious" and "serious" in dishonesty as of Decemb

2024-03-13 20:31:03 entertainment 1664℃

The Pharmaceutical Pricing and Bidding and Procurement Guidance Center of the National Medical Insurance Administration released on the 27th the status of 26 pharmaceutical companies in each province that were rated as "especially serious" and "serious" in dishonesty as of December 31, 2023. Among them, 22 pharmaceutical companies were rated as "serious" ”, 4 pharmaceutical companies were rated as “particularly serious”.

4 pharmaceutical companies rated as "particularly serious" are Sichuan Beijukang Medical Equipment Co., Ltd., Sichuan Runzeyuan Medical Equipment Co., Ltd., Zunyi Baiyi Pharmaceutical Co., Ltd., and Yunnan Jiye Pharmaceutical Co., Ltd. The 22 pharmaceutical companies rated "serious" include Beijing Nengji Traditional Chinese Medicine Beverage Co., Ltd., Taizhou Daai Medical Equipment Co., Ltd., Lianyungang Suchuang Medical Equipment Co., Ltd., etc.

By formulating a credit evaluation catalog list, the National Medical Insurance Administration has included pharmaceutical commercial bribery, tax-related violations, monopolistic practices, unfair pricing practices, disruption of centralized procurement order, malicious violation of contract agreements and other behaviors that are contrary to good faith into pharmaceutical prices and recruitment. Adoption credit evaluation scope.

Provincial centralized procurement agencies rated the dishonesty of pharmaceutical companies in the local bidding and procurement market into four levels: "general", "moderate", "serious" and "especially serious" based on the nature, circumstances, timeliness, impact and other factors of the dishonest behavior. Updated quarterly.

Based on the credit ratings of pharmaceutical companies, provincial centralized procurement agencies have adopted written reminders and warnings, relied on centralized procurement platforms to prompt risk information to purchasers, restricted or suspended bids for relevant drugs or medical consumables, and publicly disclosed untrustworthy information to the public. . When the circumstances are particularly serious, untrustworthy companies will face the risk of losing the centralized procurement market.